International consensus panel on the treatment of primary breast cancer

European Journal of Cancer

Volumn 31, Issue 11, 1995, Pages 1754-1759

  Goldhirsch, A ^a   Wood, W C ^b   Senn, H J ^c   Glick, J H ^d   Gelber, R D ^e  

^a Ospedale Civico Lugano   (Switzerland)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CONFERENCE PAPER; FEMALE; HUMAN; LYMPH NODE METASTASIS; PATHOLOGY; PROGNOSIS; BREAST CANCER; CANCER THERAPY; CONSENSUS; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; PROGNOSIS;

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE;

EID: 0029384784     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00479-3     Document Type: Article

References (16)

1. Meeting highlights adjuvant therapy for primary breast cancer
2. Adjuvant therapy of primary breast cancer
3. Systemic treatment for early breast cancer by hormonal cytotoxic or immune therapy 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women
4. Systemic treatment for early breast cancer by hormonal cytotoxic or immune therapy 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women
5. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
6. Zedeler K for the Danish Breast Cancer Cooperative Group (DBCG). Axillary dissection of level I and II lymph nodes is important in breast cancer classification
7. Late effects of adjuvant oophorectomy and chemotherapy upon pre-menopausal breast cancer patients
8. Late cardiac effects of adjuvant therapy: too soon to tell?
9. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15
10. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
11. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): findings from NSABP B-22
12. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast & Bowel Project B-16
13. Interactions of tamoxifen with cytotoxic chemo-therapy for breast cancer
14. Adjuvant chemotherapy with and without tamoxifen: five-year results from the National Surgical Adjuvant Breast and Bowel Project Trial
15. Paclitaxel (taxol)
16. Megestrol acetate for the prevention of hot flashes